Christopher W Mount
Overview
Explore the profile of Christopher W Mount including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
2544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mount C, Suva M
Neuron
. 2025 Jan;
113(2):185-186.
PMID: 39848227
Writing in Neuron, Zhang et al. identify a subpopulation of glioblastoma cells from patient tumor samples with progenitor-like features that expresses the potassium ion channel KCND2. In mouse and organoid...
2.
Lee J, Tao R, You Z, Haldipur P, Erickson A, Farooq H, et al.
Nat Genet
. 2025 Jan;
57(1):88-102.
PMID: 39753768
Transcription factors are frequent cancer driver genes, exhibiting noted specificity based on the precise cell of origin. We demonstrate that ZIC1 exhibits loss-of-function (LOF) somatic events in group 4 (G4)...
3.
Sande W, Folpe A, OConnor P, Graham D, Molligan J, Lo Y, et al.
Mod Pathol
. 2024 Nov;
38(3):100664.
PMID: 39577663
Poorly differentiated chordoma (PDC) is an aggressive subtype of chordoma characterized by SMARCB1 (INI1) loss and a dismal prognosis. It typically involves the axial skeleton, most commonly the skull base...
4.
Arrillaga-Romany I, Ford J, Dunn G, Kotton C, Mount C, Latham K
N Engl J Med
. 2024 Oct;
391(16):1529-1538.
PMID: 39442044
No abstract available.
5.
Pan Y, Hysinger J, Yalcin B, Lennon J, Byun Y, Raghavan P, et al.
Nat Neurosci
. 2024 May;
27(8):1555-1564.
PMID: 38816530
Neurogenetic disorders, such as neurofibromatosis type 1 (NF1), can cause cognitive and motor impairments, traditionally attributed to intrinsic neuronal defects such as disruption of synaptic function. Activity-regulated oligodendroglial plasticity also...
6.
Yamada-Hunter S, Theruvath J, McIntosh B, Freitas K, Lin F, Radosevich M, et al.
Nature
. 2024 May;
630(8016):457-465.
PMID: 38750365
Adoptively transferred T cells and agents designed to block the CD47-SIRPα axis are promising cancer therapeutics that activate distinct arms of the immune system. Here we administered anti-CD47 antibodies in...
7.
Greenwald A, Darnell N, Hoefflin R, Simkin D, Mount C, Gonzalez Castro L, et al.
Cell
. 2024 Apr;
187(10):2485-2501.e26.
PMID: 38653236
Glioma contains malignant cells in diverse states. Here, we combine spatial transcriptomics, spatial proteomics, and computational approaches to define glioma cellular states and uncover their organization. We find three prominent...
8.
Choi B, Gerstner E, Frigault M, Leick M, Mount C, Balaj L, et al.
N Engl J Med
. 2024 Mar;
390(14):1290-1298.
PMID: 38477966
In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal...
9.
Larson R, Kann M, Graham C, Mount C, Castano A, Lee W, et al.
Nat Commun
. 2023 Nov;
14(1):7509.
PMID: 37980341
Chimeric Antigen Receptor (CAR) T cells directed to B cell maturation antigen (BCMA) mediate profound responses in patients with multiple myeloma, but most patients do not achieve long-term complete remissions....
10.
Mount C, Gonzalez Castro L
Antibodies (Basel)
. 2022 Jun;
11(2).
PMID: 35645204
Immunotherapy has revolutionized the care of cancer patients. A diverse set of strategies to overcome cancer immunosuppression and enhance the tumor-directed immune response are in clinical use, but have not...